Butyrolactone I

Research use only, not for human use.

Butyrolactone I is an ATP-competitive inhibitor of CDK and cdc2 kinase family.

Butyrolactone I is an ATP-competitive inhibitor of CDK and cdc2 kinase family. Butyrolactone I shows antitumor effects in non-small cell lung, small cell lung, and prostate cancer cell lines.(In Vitro):Butyrolactone I (70 and 100 μM) increases the percentage of DU145 cells in the 4C phase of the cell cycle. Butyrolactone I increases the amount of cyclin B1 positive cells in the 4C phase on day 1 and returns to normal by day 3. Butyrolactone I inhibits Cdc2 of unsynchronized cultured prostate cancer cells and interrupts the cell cycle progression toward cell division. The Butyrolactone I inhibition of Cdc2 led to the accumulation of cells in the 4C phase without mitosis resulting in an accumulation of cyclin B1.

Olomoucin

Angiogenesis

CDK

Parasite

——

——

87414-49-1

424.4

C24H24O7

>98% (HPLC)

——

C([C@]1(C(OC)=O)C(=C(O)C(=O)O1)C2=CC=C(O)C=C2)C3=CC(CC=C(C)C)=C(O)C=C3

——

(-20℃)

With Ice Pack

≥ 2 years